» Articles » PMID: 25642979

Tumorspheres Derived from HCC Cells Are Enriched with Cancer Stem Cell-like Cells and Present High Chemoresistance Dependent on the Akt Pathway

Overview
Specialties Chemistry
Oncology
Date 2015 Feb 3
PMID 25642979
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Recent evidence suggests that a small subset of cells within tumors have 'stem cell-like' characteristics. However, direct proof of the population of liver CSCs remains elusive. Further research is needed to identify cells with stem cell properties in established HCC cell lines. Our previous investigation found that tumor spheres are essentially enriched in CSCs. We hypothesized that chemoresistance in hepatocellular carcinoma (HCC) is due to enrichment of cancer stem cells via the PI3K/Akt pathway. We found that tumor spheres cells formed from HCC cells contained a high percentage of CD90(+) cells, and these cells were more tumorigenic and resistant to doxorubicin (DOX), showing a higher proliferation rate and lower apoptosis rate compared to cells in monolayer culture. Treatment with DOX and PI3K/Akt inhibitor increased apoptosis and reduced viability among cells in the tumorspheres. The expression of p-Akt1 was upregulated in tumorsphere-forming cells treated with DOX but downregulated upon further treatment with the PI3K/Akt inhibitor. Our results demonstrate that HCC cells in tumorspheres with cancer stem cell properties achieve chemoresistance via the PI3K/Akt1 pathway.

Citing Articles

Enhancer of zeste homolog 2 promotes hepatocellular cancer progression and chemoresistance by enhancing protein kinase B activation through microRNA-381-mediated SET domain bifurcated 1.

Zhou J, Che J, Xu L, Yang W, Li Y, Zhou W Bioengineered. 2022; 13(3):5737-5755.

PMID: 35184652 PMC: 8974146. DOI: 10.1080/21655979.2021.2023792.


The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells.

Yin W, Xiang D, Wang T, Zhang Y, Pham C, Zhou S Sci Rep. 2021; 11(1):10791.

PMID: 34031441 PMC: 8144399. DOI: 10.1038/s41598-021-89931-9.


Cancer Stem Cells: A Potential Breakthrough in HCC-Targeted Therapy.

Wu Y, Zhang J, Zhang X, Zhou H, Liu G, Li Q Front Pharmacol. 2020; 11:198.

PMID: 32210805 PMC: 7068598. DOI: 10.3389/fphar.2020.00198.


Dysregulated lipid metabolism in hepatocellular carcinoma cancer stem cells.

Bort A, Sanchez B, de Miguel I, Mateos-Gomez P, Diaz-Laviada I Mol Biol Rep. 2020; 47(4):2635-2647.

PMID: 32125560 DOI: 10.1007/s11033-020-05352-3.


[Matrine suppresses stemness of hepatocellular carcinoma cells by regulating β-catenin signaling pathway].

Dai M, Cai Z, Chen N, Li J, Wen J, Tan L Nan Fang Yi Ke Da Xue Xue Bao. 2019; 39(10):1239-1245.

PMID: 31801708 PMC: 6867957. DOI: 10.12122/j.issn.1673-4254.2019.10.17.